Serum S100B Represents a New Biomarker for Mood Disorders
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Recently, mood disorders have been discussed to be characterized by glial pathology. The protein S100B, a growth and differentiation factor, is located in, and may actively be released by astro- and oligodendrocytes. This protein is easily assessed in human serum and provides a useful parameter for glial activation or injury. Here, we review studies investigating the glial marker S100B in serum of patients with mood disorders. Studies consistently show that S100B is elevated in mood disorders; more strongly in major depressive than bipolar disorder. Consistent with the glial hypothesis of mood disorders, serum S100B levels interact with age with higher levels in elderly depressed subjects. Successful antidepressive treatment has been associated with serum S100B reduction in major depression, whereas there is no evidence of treatment effects in mania. In contrast to the glial marker S100B, the neuronal marker protein neuron-specific enolase is unaltered in mood disorders. Recently, serum S100B has been linked to specific imaging parameters in the human white matter suggesting a role for S100B as an oligodendrocytic marker protein. In sum, serum S100B can be regarded as a promising in vivo biomarker for mood disorders deepening the understanding of the pathogenesis and plasticity-changes in these disorders. Future longitudinal studies combining serum S100B with other cell-specific serum parameters and multimodal imaging are warranted to further explore this serum protein in the development, monitoring and treatment of mood disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 2×
“S100B may even induce neurogenesis [98], which is considered specifically relevant to behavioral effects of antidepressants [99].”
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 3×
“Recently, it has been suggested that a loss of neuroplasticity and cellular resilience may underlie the pathophysiology of mood disorders and that effective long-term treatment can only be achieved by early neurotrophic and/or neuroprotective intervention [1, 2].”
Song, S.-K., Sun, S.-W., Ju, W.-K., Lin, S.-J., Cross, A. H., & Neufeld, A. H. (2003) · NeuroImage · doi:10.1016/j.neuroimage.2003.07.005 · Cited by 1,738 · cited 1×
“In addition to the most commonly assessed DTI parameter fractional anisotropy, an index for global white matter integrity, we analyzed axial and radial diffusivity as markers for axonal and myelin degeneration, respectively [104].”
Donato, R. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00046-2 · Cited by 1,580 · cited 1×
“Serum S100B is a useful biomarker for mood disorders: Concentrations of the glial marker protein S100B are elevated in patients with mood disorder, major depression and mania, when compared with healthy control subjects; Serum S100B is higher in major depressive disorder than bipolar disorder.”
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525 · cited 1×
“disorders [3, 8-11].”
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Cotter, D., Mackay, D., Landau, S., Kerwin, R., & Everall, I. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.545 · Cited by 766
Alterations in 5-HT 1B Receptor Function by p11 in Depression-Like States
Svenningsson, P., Chergui, K., Rachleff, I., Flajolet, M., Zhang, X., Yacoubi, M. E., Vaugeois, J.-M., Nomikos, G. G., & Greengard, P. (2006) · Science · doi:10.1126/science.1117571 · Cited by 572 · cited 1×
“Animal models are per se limited in their validity as models for human subjects, because psychiatric symptoms require approaches to first person perspective, phenomenological data, as in humans possible only [26].”
Electron microscopy of oligodendroglia in severe mental illness
Uranova, N., Orlovskaya, D., Vikhreva, O., Zimina, I., Kolomeets, N., Vostrikov, V., & Rachmanova, V. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00528-7 · Cited by 495
MiR-16 Targets the Serotonin Transporter: A New Facet for Adaptive Responses to Antidepressants
Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J.-M., & Kellermann, O. (2010) · Science · doi:10.1126/science.1193692 · Cited by 480
Cited by
Blood-brain barrier regulation in psychiatric disorders
Kealy, J., Greene, C., & Campbell, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2018.06.033 · Cited by 307
Depression and sterile inflammation: essential role of danger associated molecular patterns
Franklin, T. C., Xu, C., & Duman, R. S. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.10.025 · Cited by 204
The Immune System and Electroconvulsive Therapy for Depression
Guloksuz, S., Rutten, B. P. F., Arts, B., van Os, J., & Kenis, G. (2014) · The Journal of ECT · doi:10.1097/yct.0000000000000127 · Cited by 90
Steinacker, P., Al Shweiki, M. R., Oeckl, P., Graf, H., Ludolph, A. C., Schönfeldt-Lecuona, C., & Otto, M. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.09.012 · Cited by 84
Zhang, L., Verwer, R. W. H., Zhao, J., Huitinga, I., Lucassen, P. J., & Swaab, D. F. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.098 · Cited by 40
Metadata
- Authors
- Schroeter, M., Sacher, J., Steiner, J., Schoenknecht, P., & Mueller, K.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-09-01
- Volume
- 14
- Issue
- 11
- Pages
- 1237-1248
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2122499665
- Cited by
- 115
- References
- 20
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum S100B Represents a New Biomarker for Mood Disorders. https://app.cochat.ai/papers/10.2174/13894501113149990014
- The paper
- Schroeter, M., Sacher, J., Steiner, J., Schoenknecht, P., & Mueller, K. (2013). Serum S100B Represents a New Biomarker for Mood Disorders. Current Drug Targets. https://doi.org/10.2174/13894501113149990014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.